Clinical trials: Neoplasms Recurrence
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma
This phase I trial studies the side effects and best dose of CS1-chimeric antigen receptor (CAR) T therapy after chemotherapy in treating patients who have CS1 positive multiple myeloma that has come back (relapsed) or does not…
- Trial name
- NCT03710421
- Testing
- CS1-CAR T Therapy, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- City of Hope Medical Center
Head and Neck Cancer
Boron Neutron Capture Therapy (BNCT) Combined With Cetuximab in the Treatment of Locally Recurred Head and Neck Cancer
The purpose of the study is to investigate efficacy and safety boron neutron capture therapy (BNCT) administered in combination with cetuximab in the treatment of head and neck cancer that has recurred locally following…
- Trial name
- NCT00927147
- Testing
- BNCT, cetuximab
- Where
- Finland
- Volunteers
- 17 people
- Sponsor
- Boneca Corporation
Relapsed or Refractory Acute Myeloid Leukemia
Pegcrisantaspase in Combination With Venetoclax for Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)
Evaluate the safety and tolerability of pegcrisantaspase in combination with venetoclax (Ven-PegC) and estimate the maximum tolerated doses and/or biologically active doses of Ven-PegC in patients with relapsed or refractory…
- Trial name
- NCT04666649
- Testing
- Venetoclax and pegcrisantaspase
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Maryland, Baltimore
Gastric Cancer
Detection of Minimal Residual Disease Using Exosomal miRNA Distant Metastasis Markers
Gastric cancer (GC) is a leading cause of cancer-related death worldwide. Even in patients undergoing curative surgery for non-metastatic disease, postoperative recurrence frequently occurs due to undetected minimal residual…
- Trial name
- DESTINEX-REM (NCT07243015)
- Testing
- small RNA-seq or array, ENLIGHT Assay
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- City of Hope Medical Center
Cervical Cancer
Avelumab With Axitinib in Persistent or Recurrent Cervical Cancer After Platinum-based Chemotherapy
This is a single-arm, Simon's 2-stage, proof-of-concept trial. The aim is to evaluate the efficacy and safety of avelumab with axitinib in patients with persistent or recurrent cervical cancer following platinum-based…
- Trial name
- ALARICE (NCT03826589)
- Testing
- Avelumab, Axitinib
- Where
- Hong Kong
- Volunteers
- 23 people
- Sponsor
- The University of Hong Kong
Endometrial Cancer
Combination Chemotherapy With or Without G-CSF in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003691
- Testing
- filgrastim, cisplatin, doxorubicin hydrochloride
- Where
- 73 sites in United States, Canada
- Volunteers
- 240 people
- Sponsor
- Gynecologic Oncology Group
Glioma
A Study in Subjects With Recurrent Malignant Glioma
An open-label phase 2, multicenter study in participants with recurrent malignant glioma.
- Trial name
- NCT01137604
- Testing
- Lenvatinib, Bevacizumab
- Where
- 5 sites in United States, Canada
- Volunteers
- 151 people
- Sponsor
- Eisai Inc.
Breast Cancer
Docetaxel and Ifosfamide in Treating Women With Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of docetaxel and ifosfamide in treating women who have…
- Trial name
- NCT00026078
- Testing
- docetaxel, ifosfamide
- Where
- 8 sites in Argentina, Mexico
- Volunteers
- 42 people
- Sponsor
- Grupo Oncologico Cooperativo del Sur
Local Recurrence of Malignant Tumor of Soft Tissue
Role of Barrier Resection in Local Control for Extremity Recurrent Soft Tissue Sarcomas
The randomized, controlled trial is aiming at comparing local control rate between two surgical resections, barrier resection and local wide resection with 1cm or equivalent normal tissues.
- Trial name
- NCT02120768
- Testing
- barrier resection/1cm resection
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Fudan University
Breast Cancer
Gemcitabine Hydrochloride and Genistein in Treating Women With Stage IV Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine hydrochloride and genistein, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00244933
- Testing
- genistein, gemcitabine, Tumor biopsy
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
MET Positive, Recurrent Squamous Cell Lung Carcinoma
Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
This randomized phase II/III compares rilotumumab when given together with erlotinib hydrochloride against erlotinib hydrochloride alone in treating patients with stage IV squamous cell lung cancer that has come back after…
- Conditions
- MET Positive, Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7
- Trial name
- NCT02926638
- Testing
- Erlotinib Hydrochloride, Laboratory Biomarker Analysis, Rilotumumab
- Where
- 627 sites in United States
- Volunteers
- 9 people
- Sponsor
- SWOG Cancer Research Network
PD-L1-selected Solid Tumors
A Study to Evaluate the Safety and Pharmacokinetics of the Intravenous Fixed-Dose Combination (IV FDC) of Tiragolumab and Atezolizumab in Participants With Locally Advanced, Recurrent or Metastatic Solid Tumors
The purpose of this study is to assess the safety, pharmacokinetics, and immunogenicity of tiragolumab and atezolizumab intravenous fixed-dose combination (IV FDC) in participants with histologically confirmed PD-L1-selected…
- Trial name
- SKYSCRAPER-11 (NCT05661578)
- Testing
- Tiragolumab and Atezolizumab IV FDC
- Where
- 32 sites in United States, China and 7 more
- Volunteers
- 64 people
- Sponsor
- Hoffmann-La Roche
Leukemia
Oblimersen and Gemtuzumab Ozogamicin in Treating Older Patients With Relapsed Acute Myeloid Leukemia
RATIONALE: Monoclonal antibodies such as gemtuzumab ozogamicin can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00017589
- Testing
- oblimersen sodium, gemtuzumab ozogamicin
- Where
- United States
- Sponsor
- Genta Incorporated
Leukemia
S0530 Cytarabine and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
RATIONALE: Drugs used in chemotherapy, such as cytarabine and clofarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00337168
- Testing
- clofarabine, cytarabine
- Where
- 91 sites in United States
- Volunteers
- 36 people
- Sponsor
- SWOG Cancer Research Network
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
SU5416 and Irinotecan in Treating Patients With Advanced Colorectal Cancer
Phase I/II trial to study the effectiveness of combining SU5416 and irinotecan in treating patients who have advanced colorectal cancer. SU5416 may stop the growth of colorectal cancer by stopping blood flow to the tumor.
- Conditions
- Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer
- Trial name
- NCT00005818
- Testing
- irinotecan hydrochloride, semaxanib, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- National Cancer Institute (NCI)
Esophageal Cancer, GastroEsophageal Cancer
Zanidatamab Outcomes and Lived Experiences in Advanced HER2+ GEA
The purpose of this study is to collect real-world data to describe the effectiveness and tolerability of first line (1L) zanidatamab-containing therapies and describe the subsequent lines of treatment in participants with…
- Conditions
- Esophageal Cancer, GastroEsophageal Cancer, Gastroesophageal-junction Cancer, HER2-positive Gastric Cancer
- Trial name
- ZOLA (NCT07780968)
- Testing
- Zanidatamab
- Where
- 2 sites in United States
- Volunteers
- 300 people
- Sponsor
- Jazz Pharmaceuticals
Colorectal Cancer
CRC Post-surgical Assessment and Recurrence Monitoring
The surgical therapeutic effect of stage II-IV CRC patients will be assessed by the plasma mSEPT9 assay, and patients will be followed up by the same assay for recurrence monitoring.
- Trial name
- NCT03334890
- Testing
- plasma mSEPT9 level
- Where
- 4 sites in China
- Volunteers
- 50 people
- Sponsor
- BioChain (Beijing) Science and Technology, Inc.
Radiotherapy Side Effect, Locoregional Recurrence
RCT Comparing 2 Radiotherapy HypoFractionation Schedules In Breast Cancer Patients
This is a prospective randomized Phase III trial to assess efficiency of two post mastectomy hypofractionation schedules (40 Gy /15 fx / 3 weeks, 5 days per week VS 28.5 Gy delivered in 5 once-weekly fractions of 5.7 Gy each…
- Trial name
- Breastcancer (NCT04550910)
- Testing
- Hypofractionation Schedules for Breast Cancer patients after mastecomy
- Where
- Egypt
- Volunteers
- 166 people
- Sponsor
- National Cancer Institute, Egypt
Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma
Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma
Phase I/II trial to study the effectiveness of erlotinib in treating patients who have recurrent malignant glioma or recurrent or progressive meningioma.
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma
- Trial name
- NCT00045110
- Testing
- erlotinib hydrochloride, laboratory biomarker analysis, pharmacological study
- Where
- 7 sites in United States
- Volunteers
- 136 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma
Pomalidomide, Cyclophosphamide and Prednisone (PCP) in Patients With Multiple Myeloma (MM) Relapsed and/or Refractory to Lenalidomide
This study will evaluate if the combination of Pomalidomide, Cyclophosphamide and Prednisone is safe and provides benefits in patients with multiple myeloma relapsed and/or refractory to lenalidomide.
- Trial name
- PCP (NCT01166113)
- Testing
- Pomalidomide, Cyclophosphamide, Prednisone
- Where
- Italy
- Volunteers
- 67 people
- Sponsor
- Fondazione EMN Italy Onlus
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.